DNLI Q2 2024 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$117M

Net Income

-$99M

EPS (Diluted)

$-0.59

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$91M

Free Cash Flow

-$96M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$116M

Stockholders' Equity

$1.4B

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$294M	-100.0%
Gross Profit	$0	$294M	-100.0%
Operating Income	-$117M	$170M	-168.4%
Net Income	-$99M	$183M	-154.0%